The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | An overview of the different modalities used to assess MRD in AML
Firas El Chaer, MD, University of Virginia, Charlottesville, VA, discusses various modalities to assess measurable residual disease (MRD) in patients with acute myeloid leukemia (AML). Whilst multicolor flow cytometry (MFC) is a very reliable test for MRD for patients with acute lymphoblastic leukemia (ALL), other modalities such as polymerase chain reaction (PCR) and next-generation sequencing (NGS) are much more sensitive and specific for the various subtypes of AML. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
